Radiotherapy and chemotherapy in locally advanced head and neck squamous cell carcinoma

Journal of B.U.ON.

Volumn 14, Issue 3, 2009, Pages 361-373

  Krstevska, Valentina ^a  

^a University Clinic of Radiotherapy and Oncology   (Macedonia)

Author keywords

Adjuvant concurrent chemoradiotherapy; Altered fractionation; Chemotherapy; Concurrent chemoradiotherapy; Head and neck cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ACCELERATED FRACTIONATION; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DERMATITIS; EVIDENCE BASED PRACTICE; HEAD AND NECK CARCINOMA; HUMAN; HYPERFRACTIONATION; HYPOPHARYNX CARCINOMA; INTERMETHOD COMPARISON; LARYNX CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELITIS; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY DOSAGE;

EID: 70350056233     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base number 5, version 2.0. Lyon, France: IARC Press, 2004.
2. Greene FL, Page DL, Fleming ID et al. (Eds): AJCC cancer staging manual (6th edn). New York: Springer, 2002.
3. Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003; 39: 560-571. (Pubitemid 36287367)
4. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85: 156-170 (Pubitemid 47562578)
5. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol 1997; 43: 1-21.
6. Withers RH. Biologic basis for altered fractionation schemes. Cancer 1985; 55: 2086-2095.
7. Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 405-417. (Pubitemid 44192922)
8. Garden AS. Altered fractionation for head and neck cancer. Oncology 2001; 15: 1334-1340.
9. Thames HD, Withers HR, Peters LJ et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219-226.
10. Pinto LHJ, Canary PCV, Araujo CMM, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionation versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991; 21: 557-562.
11. Cummings B, Keane T, Pintilie M et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 2007; 85: 7-16. (Pubitemid 47562589)
12. Horiot JC, Le Fur R, N 'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25: 231-241 (Pubitemid 23000765)
13. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16. (Pubitemid 30488207)
14. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1998; 27: 131-146.
15. Overgaard J, Sand Hansen H, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomized controlled trial. Lancet 2003; 362: 933-940. (Pubitemid 37159288)
16. Hliniak A, Gwiazdowska B, Szutkowski Z et al. A multicentre randomized/ controlled trial of a conventional versus modestly accelerated radiotherapy in laryngeal cancer: influence of a 1 week shortening overall time. Radiother Oncol 2002; 62: 1-10. (Pubitemid 34121944)
17. Skladowski K, Maciejewski J, Golen M, Pilecki B, Przeorek W, Tarnawski R. Randomized clinical trial of 7-day continuous accelerated irradiation (CAIR) of head and neck cancer: report on 3-year tumor control and normal tissue toxicity. Radiother Oncol 2000; 55: 93-102.
18. Dische S, Saunders MC, Barrett A, Harvey A, Gibson D, Parmer M. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-136. (Pubitemid 27345199)
19. Bourhis J, Lapeyre M, Tortochaaux J et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006; 24: 2873-2878. (Pubitemid 46630588)
20. Horiot J-C, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111-121. (Pubitemid 27345198)
21. Suwinski R, Bankowska-Wozniak M, Majewski W et al. Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer. Radiother Oncol 2008; 87: 155-163.
22. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854. (Pubitemid 44292807)
23. Budach W, Her T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28. (Pubitemid 43298521)
24. Bernier J, Cooper YS. Chemoradiation after surgery for high-risk head and neck patients: how strong is the evidence? The Oncologist 2005; 10: 215-224.
25. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002; 9: 387-399. (Pubitemid 35204461)
26. Merlano M, Benasso M, Corvò R et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in the treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583-589. (Pubitemid 26139938)
27. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
28. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76. (Pubitemid 41095116)
29. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18: 3320-3321. (Pubitemid 30205391)
30. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161-1171. (Pubitemid 32727792)
31. Wendt TG, Grabenbauer GG, Rödel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-1324.
32. Brizel DM, Albers Mary E, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804. (Pubitemid 28277960)
33. Seiwert TY, Cohen EE. State-of-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341-1348.
34. Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83-91.
35. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14:838-847. (Pubitemid 26085529)
36. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-955.
37. Bourhis J, Amand C, Pignon JP. MACH-NC Collaborative Group. Update of MACH-NC (meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemotherapy. J Clin Oncol 2004; 22: S5505.
38. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-589.
39. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987; 60: 1178-1183.
40. Karp DD, Vaughan CW, Carter R et al. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report. Am J Clin Oncol 1991; 14: 273-279.
41. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
42. Lefebre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-899. (Pubitemid 26230640)
43. Richard JM, Sancho-Garnier H, Pessey JJ et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224-228. (Pubitemid 28267175)
44. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
45. Pfister DG, Laurie SA, Weinstein GS et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24: 3693-3704. (Pubitemid 46630546)
46. Vokes EE, Kies MS, Haraf DJ et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000; 18: 1652-1661. (Pubitemid 30220543)
47. Adelstein DJ, Saxton JP, Lavertu P et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002; 20: 1405-1410. (Pubitemid 34177449)
48. Domenge C, Hill C, Lefebre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-1598.
49. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272. (Pubitemid 24057404)
50. Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717. (Pubitemid 39591589)
51. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer (the TAX 324 trial). N Engl J Med 2007; 357: 1705-1715. (Pubitemid 350005152)
52. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645. (Pubitemid 46211506)
53. Posner MR. Paradigm shift in the treatment of Head and Neck Cancer: the role of neoadjuvant chemotherapy. Oncologist 2005; 10(Suppl 3): 11-19. (Pubitemid 43152726)
54. Cooper JS, Pajak TF, Forastiere A et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 1998; 20: 588-594. (Pubitemid 28405799)
55. Ang KK, Trotti A, Brown BW et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 571-578. (Pubitemid 32946890)
56. Sanguineti G, Richetti A, Bignardi M et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys 2005; 61: 762-771. (Pubitemid 40247971)
57. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952. (Pubitemid 38580197)
58. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.